Circadian rhythm of ornithine decarboxylase and its endogenous high molecular weight inhibitor in rat pineal gland]

The biochemical mechanisms involved in circadian variations of the activity of ornithine decarboxylase (EC 4.1.1.17)--the rate-limiting enzyme of polyamine biosynthesis in rat pineal gland were studied. The enzyme was separated from its endogenous high molecular weight inhibitor by gel-filtration of the cytosol fraction from this organ through Sephadex G-100 in the presence of 250 mM NaCl. The inhibitor was similar in its molecular weight (30 000) and activity to ornithine decarboxylase inhibior from rat liver. The amount of the enzyme in the pineal gland undergoes much smaller circadian variations as compared to that of the inhibitor. It is concluded that the circadian variations of the ornithine decarboxylase activity in the pineal gland may be largely due to the changes in the enzyme/inhibitor ratio.     

Changes in ornithine decarboxylase activity in the developing parotid salivary gland

Ornithine decarboxylase activity in the rat parotid salivary gland was estimated during the early postnatal development. Regular alterations of enzymatic activity were found in different periods of gland development. The data obtained were compared with the evidence on the establishment of protein synthesis circahoralian rhythm of this organ in ontogenesis. The ornithine decarboxylase activity, being rather high in the parotid gland as long as up to the 20th-21st days, decreases during the termination of differentiation in this organ. It rises simultaneously with the emergence of circahoralian rhythm of protein synthesis.     

Endogenous opioid system in the realization of the analgesic effect of alpha-tocopherol in reference to algomenorrhea

Beta-endorphin-like immunoreactivity was studied in 7 patients with algomenorrhea during pain attack and 15 minutes after alpha-tocopherol administration with a therapeutic aim (till the analgetic effect was reached). There was an increase in beta-endorphin-like immunoreactivity after alpha-tocopherol administration. Naloxone administration to 9 patients with algomenorrhea of various etiology resumed the pain. The effect of alpha-tocopherol application for pain relief depended on the pathogenesis of algomenorrhea. At the same time naloxone administration failed to resume the pain in patients, in whom alpha-tocopherol had a strong analgetic effect. It is assumed that the endogenous opioid system participates in alpha-tocopherol effect on pain relief in patients with algomenorrhea.     

Effect of the hexapeptide dalargin on ornithine decarboxylase activity in the duodenal mucosa of rats in experimental duodenal ulcer

The effect of an opioid antiulcerogenic hexapeptide dalargin on ornithine decarboxylase activity of duodenal mucosa has been studied in rats with experimental duodenal ulcers induced by cysteamine. The intraperitoneal injection of 12.5 micrograms/kg of dalargin inhibited ulcerogenesis and activated the enzyme. The effect of the peptide was antagonized by an opiate antagonist naloxone. 5000 micrograms/kg of dalargin failed to inhibit the ulcer formation or to activate ornithine decarboxylase. Since ornithine decarboxylase activation is a marker of intensified cell proliferation and tissue regeneration, our results suggest that the antiulcerogenic effect of dalargin is due to the enhancement of duodenal mucosa regeneration.     

Specific binding of N-allylnormetazocine (SKF 10047), a ligand of sigma-opioid receptors, with liver membranes

A sigma-opioid receptor ligand, N-allylnormetazocine (SKF 10047), binds specifically and reversibly to rat liver membranes. The rat liver binding sites for SKF 10047 are similar to sigma-opioid CNS receptors. They fail to interact with classical opiates (morphine, naloxone) and opioid peptides but bind with high affinity benzomorphans (bremazocine, SKF 10047) and various psychotropic drugs (haloperidol, imipramine, phencyclidine etc).     

Implantation of embryonic pancreas into the anterior chamber of healthy and diabetic rats

The possibility of pancreatic-islet embryonic implantation into the frontal chamber of the eye in Wistar rats has been demonstrated. The implantation was followed by the induction of alloxan diabetes. Clinical diabetic compensation has been shown in a number of experimental animals (maximum time of experiments--45 days). The formation of islet-like structures in the frontal chamber of the eye was confirmed microscopically. The structures contained B cells in their cytoplasm. Cellular differentiation leading to the appearance of functionally active endocrine cells has been noted in the implants.